ESG401

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ESG401, covering 2025-06-19 to 2025-09-23. Get the full timeline:

Most recent: Clinical Trial Update: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]